Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer
The AJMUC1 clinical trial, sponsored by Sun Yat-Sen Memorial Hospital, explores a novel immunotherapy approach for advanced MUC1-positive breast cancer, a population with limited effective treatment options. The trial's completion in November 2022 positions it for potential market entry, contingent on favorable safety and efficacy results. The competitive landscape includes established CAR-T therapies and emerging immunotherapies targeting similar malignancies. The success of AJMUC1 could provide a unique therapeutic avenue, particularly for patients who have exhausted standard treatment options, thereby addressing a significant unmet medical need. Diligence should focus on the trial's safety profile, potential market size, and the regulatory pathway for CAR-T therapies in China and globally.
Indication: Advanced Breast Cancer
Modality: gene therapy
Target: PD-1 knockout anti-MUC1 CAR-T cells targeting aberrantly glycosylated MUC1 protein.
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-1 knockout anti-MUC1 CAR-T cells targeting aberrantly glycosylated MUC1 protein.
View original source fields
Condition raw: Advanced Breast Cancer, Breast Neoplasm Malignant Female
Condition normalized: Advanced Breast Cancer, Breast Neoplasm Malignant Female
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: PD-1 knockout anti-MUC1 CAR-T cells targeting aberrantly glycosylated MUC1 protein.
Target normalized: PD-1 knockout anti-MUC1 CAR-T cells targeting aberrantly glycosylated MUC1 protein.